Seaport Therapeutics begins Phase 2a trial of GlyphAgo for anxiety

Seaport Therapeutics (NASDAQ:SPTX) has dosed the first patient in a Phase 2a clinical trial in Australia for its drug candidate GlyphAgo (SPT), which is being evaluated for generalized anxiety disorder and sleep disturbance.